Estimation of influenza and respiratory syncytial virus hospitalizations using sentinel surveillance data-La Paz, Bolivia. 2012-2017.


Journal

Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007

Informations de publication

Date de publication:
09 2019
Historique:
received: 22 02 2019
revised: 17 05 2019
accepted: 21 05 2019
pubmed: 18 6 2019
medline: 13 2 2020
entrez: 18 6 2019
Statut: ppublish

Résumé

The objective was to estimate the number of hospitalizations associated with influenza and RSV using data from severe acute respiratory infection (SARI) sentinel surveillance from El Alto-La Paz. Bolivia. All persons who met the case definition for SARI at one sentinel hospital had a clinical sample collected and analyzed by rRT-PCR for influenza and by indirect immunofluorescence for RSV. The SARI-influenza and SARI-RSV case counts were stratified by six age groups. The proportion of cases captured in the sentinel hospital in relation to the non-sentinel hospitals of area was multiplied by the age-specific census population, to build the denominators. The annual incidence and a 95% confidence interval (CI) were estimated. During 2012-2017, n = 2606 SARI cases were reported (average incidence 120/100 000 inhabitants [95% CI: 116-124]); the average incidence of influenza-associated SARI hospitalization was 15.3/100 000 (95% CI: 14.1-16.7), and the average incidence of RSV-associated SARI hospitalization was 9/100 000 inhabitants (95% CI: 8.1-10.1). The highest incidence of influenza was among those less than one year of age (average 174.7/100 000 [range: 89.1-299.5]), followed by those one to four years of age (average 51.8/100 000 [range: 19.8-115.4]) and then those 65 years of age and older (average 47.7/100 000 [range: 18.8-117]). For RSV, the highest incidence was highest among those less than one year of age (231/100 000 [range: 119.9-322.9]). Influenza and RSV represent major causes of hospitalization in La Paz, Bolivia-with the highest burden among children under one year of age. Our estimates support current prevention strategies in this age group.

Identifiants

pubmed: 31206257
doi: 10.1111/irv.12663
pmc: PMC6692540
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

477-483

Informations de copyright

© 2019 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

Références

Expert Rev Pharmacoecon Outcomes Res. 2014 Jun;14(3):425-35
pubmed: 24734967
Influenza Other Respir Viruses. 2019 Sep;13(5):477-483
pubmed: 31206257
PLoS Pathog. 2011 Sep;7(9):e1002225
pubmed: 21909272
J Pediatr. 2010 Nov;157(5):808-14
pubmed: 20580018
Bull World Health Organ. 2012 Oct 1;90(10):756-63
pubmed: 23109743
Lancet. 2011 Dec 3;378(9807):1917-30
pubmed: 22078723
BMC Public Health. 2011 Nov 24;11:885
pubmed: 22111590
Influenza Other Respir Viruses. 2018 Jan;12(1):132-137
pubmed: 29446233
PLoS One. 2013;8(2):e56882
pubmed: 23573177
PLoS One. 2015 Mar 04;10(3):e0118369
pubmed: 25738736
JAMA. 2004 Sep 15;292(11):1333-40
pubmed: 15367555
Influenza Other Respir Viruses. 2018 Jan;12(1):138-145
pubmed: 29446231
Soc Sci Med. 2003 Mar;56(6):1173-82
pubmed: 12600356
Emerg Infect Dis. 2006 Jan;12(1):103-9
pubmed: 16494725
Vaccine. 2012 Mar 23;30(14):2448-52
pubmed: 22300721
BMC Infect Dis. 2018 Jun 8;18(1):269
pubmed: 29884140
Influenza Other Respir Viruses. 2016 Jul;10(4):340-5
pubmed: 26946216
J Glob Health. 2015 Dec;5(2):020101
pubmed: 26755941
Lancet. 2013 Apr 20;381(9875):1380-1390
pubmed: 23369797
Hum Vaccin Immunother. 2013 Apr;9(4):834-40
pubmed: 23357859
BMC Infect Dis. 2015 Oct 24;15:447
pubmed: 26497393
PLoS One. 2014 Nov 25;9(11):e113903
pubmed: 25423025
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Am J Respir Crit Care Med. 2013 Sep 15;188(6):710-5
pubmed: 23855650
Emerg Infect Dis. 2014 May;20(5):878-81
pubmed: 24750897
Lancet. 2003 Nov 22;362(9397):1733-45
pubmed: 14643124
Lancet Infect Dis. 2017 Oct;17(10):e320-e326
pubmed: 28457597

Auteurs

Dabeyva Chavez (D)

Minister of Health, La Paz, Bolivia.

Vicente Gonzales-Armayo (V)

Minister of Health, La Paz, Bolivia.

Elvis Mendoza (E)

Servicio Departamental de Salud, La Paz, Bolivia.

Rakhee Palekar (R)

Pan American Health Organization, WDC, USA.

Rosario Rivera (R)

Instituto de Laboratorios en Salud INLASA, La Paz, Bolivia.

Angel Rodriguez (A)

Pan American Health Organization, WDC, USA.

Claudia Salazar (C)

Servicio Departamental de Salud, La Paz, Bolivia.

Angel Veizaga (A)

Hospital Boliviano Holandés, El Alto, Bolivia.

Arletta Añez (A)

Pan American Health Organization, La Paz, Bolivia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH